WMS Partners’s Axsome Therapeutics AXSM Stock Holding History

WMS Partners’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Hold	0	–	-$1.54M	–	280
2022 Q4	–	Hold	0	–	–	–	73

Other funds holding AXSM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WMS Partners's AXSM Position: Q3 2024 in Review

WMS Partners sold out of Axsome Therapeutics (AXSM) in Q3 2024, closing a stake of 40,711 shares — an estimated $3.28M sold.

WMS Partners first reported a position in AXSM in Q2 2020 and held it in 17 quarters. The position peaked at $20.6M in Q2 2020. 279 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

WMS Partners reported no remaining Axsome Therapeutics position as of Q3 2024 after selling out during the quarter.
WMS Partners sold 40,711 Axsome Therapeutics shares in Q3 2024, an estimated $3.28M.
WMS Partners first reported a position in Axsome Therapeutics in Q2 2020 and held it in 17 quarters.
WMS Partners's Axsome Therapeutics position peaked at $20.6M in Q2 2020.
279 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on WMS Partners's 13F filing for Q3 2024, filed 13 Nov 2024.